6:01 PM · 13 April 2021

Moderna stock rose 7% after FDA halt use of JNJ vaccine

The news that the Johnson & Johnson (JNJ.US) vaccine would be paused appeared to be beneficial for Moderna (MRNA.US) which shares gained more than 7% following FDA announcement. The drugmaker has also issued a statement saying that data indicates its COVID-19 vaccine is not associated with cerebral venous sinus thrombosis ("CVST") or other thrombotic events. Moderna announced that assessment was made based on safety data through March 22 of more than 64.5M doses administered worldwide.

Moderna (MRNA.US) stock launched today's session with a bullish price gap and is currently testing the upper limit of the descending channel which coincides with 50 SMA (green line). Source: xStation5

17 September 2026, 7:17 PM

Daily Summary: Hawkish Fed fails to scare the markets (17.09.2026)

17 September 2026, 6:46 PM

Nasdaq 100 Up 1.7%

17 September 2026, 4:45 PM

US Open: Nasdaq, gold and silver surge following... an interest rate hike (17.09.2026)

16 September 2026, 6:05 PM

JB Hunt shares down 13% 📉 US transportation stocks have problems?

The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits